ALK and neuroblastoma: Treatment of neuroblastoma xenograft models with CDX0239-PBD led to maintained complete response in NB-1, NB-SD, COG-N-424x, and NGP ALK WT, and a partial response with subsequent tumor growth progression in SK-N-AS (Fig. 6A).